Donor Natural Killer Cells and Hu3F8 in Treating Patients with High-Risk Neuroblastoma

Inclusion Criteria

• Diagnosis of NB as defined by international criteria, i.e., histopathology (confirmed by the Memorial Sloan Kettering Cancer Center [MSKCC] Department of Pathology) or bone marrow metastases plus high urine catecholamine levels
• High-risk NB as defined by risk-related treatment guidelines' and the International NB Staging System, i.e., stage 4 with (any age) or without (> 18 months of age) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), or MYCN-amplified stage 4S
• Patients must have a history of tumor progression or persistent disease or failure to achieve complete response following standard therapy
• Patients must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive metaiodobenzylguanidine [MIBG] or positron emission tomography [PET] scans) or measurable (computed tomography [CT], magnetic resonance imaging MRI]) disease documented after completion of prior systemic therapy
• Disease staging approximately within one month of treatment
• Prior treatment with murine and hu3F8 is allowed; patients with prior humanizing murine IgG3 anti-GD2 antibody m3F8 (m3F8), hu3F8, ch14.18 or hu14.18 treatment must have human anti-human antibody (HAHA) antibody titer; human anti-mouse antibody (HAMA) positivity is allowed
• Eligible NK donor
• Signed informed consent indicating awareness of the investigational nature of this program
• DONOR: Donor is blood-related and HLA-haploidentical to the recipient
• DONOR: Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors; tests include but are not limited to: hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, hepatitis C antibody, Epstein-Barr virus antibody, human immunodeficiency virus (HIV), human T-cell leukemia virus (HTLV) I and II, varicella zoster (herpes zoster), herpes simplex antibody, cytomegalovirus antibodies, syphilis (rapid plasma reagin [RPR] profile) for adolescents and adults, measles for pediatric patients, West Nile virus, Chagas screen, and toxoplasma antibodies; donor must have normal negative test results for HIV, HTLV I and II, and West Nile virus; donor exposure to other viral pathogens will be discussed on a case-by-case basis by investigators
• DONOR: Donor must be able to undergo leukapheresis for total volume of 10-15 liters
• DONOR: There is no age restriction for the donor

Exclusion Criteria

• Patients with complete response (CR)/very good partial response (VGPR) disease
• Existing severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade 3 except for hearing loss, alopecia, anorexia, nausea, hyperbilirubinemia and hypomagnesemia from total parenteral nutrition (TPN), which may be grade 3
• Absolute neutrophil count (ANC) should be > 500/uL
• Platelet count > 75 K/uL
• History of allergy to mouse proteins
• Active life-threatening infection
• Inability to comply with protocol requirements
• Women who are pregnant or breast-feeding
• DONOR: Cardiac risk factors precluding ability to undergo leukapheresis
• DONOR: Concurrent malignancy or autoimmune disease
• DONOR: Donor is pregnant